ClinicalTrials.gg
CompletedNCT02182206Updated Jul 18, 2014

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

A Phase 1 interventional study of BIBF 1120 in Tumors, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))

02

Conditions studied

  • Tumors

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients with confirmed diagnosis of advanced, non resectable and/or solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who were not amenable to established forms of treatment
  • Measurable tumour deposits by one or more techniques (X-ray), Computed Tomography (CT), Magnetic Resonance Imaging (MRI))
  • At least one tumour lesion considered suitable for DCE-MRI as determined by discussion with centre radiologist. This lesion must not have been previously irradiated
  • Age 18 years or older
  • of at least three months
  • Written given consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines
  • (ECOG) performance score 0 or 1
  • Patients completely recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies

Exclusion criteria

Exclusion Criteria:

  • Surgical procedures within four weeks of initiating treatment with the study drug, active ulcers, or injuries with incomplete wound healing
  • Active infectious disease
  • Uncontrolled, severe hypertension (diastolic BP (Blood Pressure) >100 mmHg, Systolic BP>180 mmHg)
  • Gastrointestinal disorders that might have interfered with the resorption of the study drug
  • Serious illness or concomitant non-oncological disease considered by the investigator to have been incompatible with the protocol
  • requiring therapy
  • less than 1500/mm3
  • count less than 100 000/mm3
  • greater than 1.5 mg/dl (>26 μmol/L, System International (SI) unit equivalent)
  • Aspartate amino transferase () and / or alanine amino transferase (ALT) greater than three times the (if related to liver greater than five times the upper limit of normal)
  • Serum creatinine greater than 1.5 mg/dl (>132μmol/L, SI unit equivalent)
  • Women and men who were sexually active and unwilling to use a medically acceptable method of
  • Pregnancy or breastfeeding
  • Treatment with other drugs; chemotherapy or hormone therapy (excluding Lutenizing Hormone Releasing Hormone (LHRH) agonists or bisphosphonates provided the lesion for MR (magnetic resonance) imaging did not arise from bone) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study
  • Patients unable to comply with the protocol
  • Active alcohol or drug abuse
  • History of disease
  • History of allergy to gadolinium or other intravenous (IV) contrast agent, indwelling medical devices or any other condition that would preclude MR scanning
  • Patients requiring the ongoing use of dexamethasone, anti-histamines, anti-hypertensives or medications for the control of cardiac failure such as diuretics, where there was likely to be a need for alteration of dose during the study period. Dose adjustment of such medications may have independently altered vascular permeability or blood flow
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    BIBF 1120

    Drug: BIBF 1120

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of BIBF 1120

    Time frame: Up to 7 months

  2. Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120

    Time frame: Up to 7 months

Secondary outcomes

  1. Transfer constant (Ktrans)

    Time frame: Screening, day 2, 28 and 56

  2. Extravascular-extracellular leakage volume (ve)

    Time frame: Screening, day 2, 28 and 56

  3. Area under the gadolinium concentration time curve [0-60 seconds] (AUC[Gd])

    Time frame: Screening, day 2, 28 and 56

  4. Relative blood volume (rBV)

    Time frame: Screening, day 2, 28 and 56

  5. Mean transit time (MTT)

    Time frame: Screening, day 2, 28 and 56

  6. Relative blood flow (rBF)

    Time frame: Screening, day 2, 28 and 56

  7. Volume of tumour showing contrast uptake

    Time frame: Screening, day 2, 28 and 56

  8. Volume of tumour showing no contrast uptake

    Time frame: Screening, day 2, 28 and 56

  9. Restricted diffusion

    Time frame: Screening, day 2, 28 and 56

  10. Vessel size index

    Time frame: Screening, day 2, 28 and 56

  11. Change in Eastern Cooperative Oncology Group (ECOG) performance score

    Time frame: Baseline, up to 7 months

  12. Objective tumour responses according to the response evaluation criteria in solid tumour (RECIST)

    Time frame: Baseline, up to 7 months

  13. Area under the plasma concentration-time curve following the first dose of uniform intervals τ over the time interval from zero to 24 hours (AUCτ,1)

    Time frame: up to 24 hours after the first dose on day 1

  14. Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable drug concentration (AUC0-tz)

    Time frame: up to 24 hours after the first dose on day 1

  15. Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-∞)

    Time frame: up to 24 hours after the first dose on day 1

  16. Maximum measured plasma concentration following the first dose of uniform intervals τ (Cmax,1)

    Time frame: up to 24 hours after the first dose on day 1

  17. Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax,1)

    Time frame: up to 24 hours after the first dose on day 1

  18. Terminal half-life (t1/2)

    Time frame: up to 24 hours after the first dose on day 1

  19. Mean residence time (MRTpo)

    Time frame: up to 24 hours after the first dose on day 1

  20. Apparent clearance (CL/F)

    Time frame: up to 24 hours after the first dose on day 1

  21. Apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: up to 24 hours after the first dose on day 1

  22. Area under the plasma concentration-time curve over the dosing interval τ (24 h) at steady state (AUCτ,ss)

    Time frame: up to 24 hours after drug administration on day 27

  23. Predose plasma concentration at steady state immediately before dosing (Cpre,ss)

    Time frame: up to 24 hours after drug administration on day 27

  24. Maximum plasma concentration at steady state over the dosing interval τ (Cmax,ss)

    Time frame: up to 24 hours after drug administration on day 27

  25. Time from dosing to the maximum plasma concentration at steady state over the dosing interval τ (tmax,ss)

    Time frame: up to 24 hours after drug administration on day 27

  26. Terminal half-life at steady state (t1/2,ss)

    Time frame: up to 24 hours after drug administration on day 27

  27. Apparent clearance at steady state (CL/F,ss)

    Time frame: up to 24 hours after drug administration on day 27

  28. Mean residence time at steady state (MRTpo,ss),

    Time frame: up to 24 hours after drug administration on day 27

  29. Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)

    Time frame: up to 24 hours after drug administration on day 27

  30. Accumulation ratio (RA)

    Time frame: up to 24 hours after drug administration on day 27

  31. Minimum measured plasma concentration following the first dose of uniform intervals τ (Cmin,1)

    Time frame: up to 24 hours after the first dose on day 1

  32. Time from first dosing to the minimum plasma concentration over the dosing interval τ (tmin,1)

    Time frame: up to 24 hours after the first dose on day 1

  33. Minimum measured plasma concentration at steady state over the dosing interval τ (Cmin,ss)

    Time frame: up to 24 hours after drug administration on day 27

  34. Time from last dosing to the minimum plasma concentration at steady state over the dosing interval τ (tmin,ss)

    Time frame: up to 24 hours after drug administration on day 27

  35. Predose concentration of the 15th dose over the dosing interval τ (Cpre,15)

    Time frame: pre-dose on day 15

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ. Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250. Epub 2015 Mar 20. PubMed 25795637 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a primary completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Jun 2003
Primary completionActual
Jun 2005
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02182206
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jun 2003
Primary completion
Jun 2005
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion